Evercore ISI Group Maintains Outperform on Madrigal Pharmaceuticals, Lowers Price Target to $649
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. MDGL | 0.00 |
Evercore ISI Group analyst Liisa Bayko maintains Madrigal Pharmaceuticals (NASDAQ:
MDGL) with a Outperform and lowers the price target from $652 to $649.